Top of this page
Skip navigation, go straight to the content

UCB history in Australia

1981

  • UCB Australia was incorporated as a company on 31st March

2001

  • Keppra® (levetiracetam), is registered for use in Australia for epilepsy

2007

  • Neupro® (rotigotine) is registered for use in Australia for Parkinson’s disease

2009

  • Cimzia® (certolizumab pegol) is registered for use in Australia for Rheumatoid Arthritis
  • Vimpat® (lacosamide) is registered for use in Australia in epilepsy.

2015

  • UCB is delivering on its growth promise with double digit growth of revenues and profitability. With major pipeline milestones reached in 2015, the company is paving the way for the future with promising assets meant to further create value for patients